Brief intraperitoneal radioimmunotherapy of small peritoneal carcinomatosis using high activities of noninternalizing 125I-labeled monoclonal antibodies

Journal of Nuclear Medicine

Volumn 51, Issue 11, 2010, Pages 1748-1755

  Boudousq, Vincent ^a,b,c,d   Ricaud, Stéphanie ^a,b,c   Garambois, Véronique ^a,b,c   Bascoul Mollevi, Caroline ^c   Boutaleb, Samir ^a,b,c   Busson, Muriel ^a,b,c   Quenet, François ^c   Colombo, Pierre Emmanuel ^c   Bardiès, Manuel ^e   Kotzki, Pierre Olivier ^a,b,c,d   Navarro Teulon, Isabelle ^a,b,c   Pèlegrin, André ^a,b,c   Pouget, Jean Pierre ^a,b,c,f  

^a INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

^b UNIV MONTPELLIER   (France)

^c CENTRE VAL D AURELLE   (France)

^d NÎMES UNIVERSITY HOSPITAL   (France)

^e INSERM   (France)

^f INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE IRSN   (France)

Author keywords

Auger electrons; Peritoneal carcinomatosis; Radioimmunotherapy

Indexed keywords

CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY I 125; IMMUNOGLOBULIN G1 ANTIBODY; MONOCLONAL ANTIBODY I 125; PX I 125; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ADD ON THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; BLOOD CELL COUNT; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CONTROLLED STUDY; DOSIMETRY; DRUG DISTRIBUTION; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; PERITONEAL CAVITY; PRIORITY JOURNAL; RADIOACTIVITY; RADIOIMMUNOTHERAPY; SMALL PERITONEAL CARCINOMATOSIS; SURVIVAL TIME; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; FEMALE; IODINE RADIOISOTOPES; MICE; PERITONEAL CAVITY; PERITONEAL NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOMETRY; STAINING AND LABELING; SURVIVAL ANALYSIS; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79851488201     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.080226     Document Type: Article

References (32)

1. Glehen O, Mohamed F, Gilly FN. Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol. 2004;5:219-228. (Pubitemid 38391217)
2. Glockzin G, Schlitt HJ, Piso P. Peritoneal carcinomatosis: patients selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol. 2009;7:5.
3. Sugarbaker PH. Comprehensive management of peritoneal surface malignancy using cytoreductive surgery and perioperative intraperitoneal chemotherapy: the Washington Cancer Institute approach. Expert Opin Pharmacother. 2009; 10:1965-1977.
4. Sugarbaker PH, Cunliffe WJ, Belliveau J, et al. Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin Oncol. 1989;16:83-97. (Pubitemid 19215266)
5. Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28:63-68.
6. Elias D, Gilly F, Quenet F, et al. Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol. 2010;36:456-462.
7. Koppe MJ, Bleichrodt RP, Oyen WJG, Boerman OC. Radioimmunotherapy and colorectal cancer. Br J Surg. 2005;92:264-276. (Pubitemid 40445588)
8. Aarts F, Hendriks T, Boerman OC, Koppe MJ, Oyen WJG, Bleichrodt RP. A comparison between radioimmunotherapy and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis of colonic origin in rats. Ann Surg Oncol. 2007;14:3274-3282. (Pubitemid 47594277)
9. Aarts F, Bleichrodt R, de Man B, Lomme R, Boerman O, Hendriks T. The effects of adjuvant experimental radioimmunotherapy and hyperthermic intraperitoneal chemotherapy on intestinal and abdominal healing after cytoreductive surgery for peritoneal carcinomatosis in the rat. Ann Surg Oncol. 2008;15:3299-3307.
10. Koppe MJ, Soede AC, Pels W, et al. Experimental radioimmunotherapy of small peritoneal metastases of colorectal origin. Int J Cancer. 2003;106:965-972. (Pubitemid 37071679)
11. Kinuya S, Yokoyama K, Fukuoka M, et al. Intraperitoneal radioimmunotherapy to treat the early phase of peritoneal dissemination of human colon cancer cells in a murine model. Nucl Med Commun. 2007;28:129-133. (Pubitemid 46043273)
12. Elgqvist J, Andersson H, Bäck T, et al. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with 211At-labeled monoclonal antibody MX35. J Nucl Med. 2005; 46:1907-1915. (Pubitemid 46196654)
13. Milenic DE, Brady ED, Garmestani K, Albert PS, Abdulla A, Brechbiel MW. Improved efficacy of alpha-particle-targeted radiation therapy: dual targeting of human epidermal growth factor receptor-2 and tumor-associated glycoprotein 72. Cancer. 2010;116:1059-1066.
14. Meredith RF, Buchsbaum DJ, Alvarez RD, LoBuglio AF. Brief overview of preclinical and clinical studies in the development of intraperitoneal radio-immunotherapy for ovarian cancer. Clin Cancer Res. 2007;13:5643s-5645s.
15. 90yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res. 2002;8:2806-2811.
16. Epenetos AA, Hird V, Lambert H, Mason P, Coulter C. Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy. Int J Gynecol Cancer. 2000;10:44-46. (Pubitemid 30220628)
17. Meredith RF, Partridge EE, Alvarez RD, et al. Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49. J Nucl Med. 1996;37:1491-1496. (Pubitemid 26321629)
18. Hird V, Maraveyas A, Snook D, et al. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer. 1993;68:403-406.
19. Nicholson S, Gooden CS, Hird V, et al. Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: a matched analysis. Oncol Rep. 1998;5:223-226.
20. Verheijen RH, Massuger LF, Benigno BB, et al. Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol. 2006;24:571-578. (Pubitemid 46655592)
21. 211At-MX35 F(ab')2 - a phase I study. J Nucl Med. 2009;50:1153-1160.
22. Santoro L, Boutaleb S, Garambois V, et al. Noninternalizing monoclonal antibodies are suitable candidates for 125I radioimmunotherapy of small-volume peritoneal carcinomatosis. J Nucl Med. 2009;50:2033-2041.
23. Pouget JP, Santoro L, Raymond L, et al. Cell membrane is a more sensitive target than cytoplasm to dense ionization produced by Auger electrons. Radiat Res. 2008;170:192-200.
24. Köhler G, Howe S, Milstein C. Fusion between immunoglobulin- secreting and nonsecreting myeloma cell lines. Eur J Immunol. 1976;6:292-295.
25. Loevinger R, Budinger T, Watson E. MIRD Primer for Absorbed Dose Calculations. Revised ed. New York, NY: Society of Nuclear Medicine; 1991.
26. Goldenberg DM. Adjuvant and combined radioimmunotherapy: problems and prospects on the road to Minerva. J Nucl Med. 2006;47:1746-1748. (Pubitemid 47544995)
27. Ychou M, Azria D, Faurous P, et al. Adjuvant radioimmunotherapy trial with iodine-131-labeled anti-CEA monoclonal antibody F6 F(ab9)2 after resection of liver metastases from colorectal cancer. Clin Cancer Res. 2008;14:3487-3493.
28. DeNardo SJ, Kukis DL, Kroger LA, et al. Synergy of Taxol and radio-immunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts. Proc Natl Acad Sci USA. 1997;94:4000-4004. (Pubitemid 27180488)
29. Supiot S, Gouard S, Charrier J, et al. Mechanisms of cell sensitization to alpha radioimmunotherapy by doxorubicin or paclitaxel in multiple myeloma cell lines. Clin Cancer Res. 2005;11:7047s-7052s.
30. Burke PA, DeNardo SJ, Miers LA, Lamborn KR, Matzku S, DeNardo GL. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radio-immunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res. 2002;62:4263-4272.
31. Pedley RB, El-Emir E, Flynn AA, et al. Synergy between vascular targeting agents and antibody-directed therapy. Int J Radiat Oncol Biol Phys. 2002;54:1524-1531. (Pubitemid 35380059)
32. Chatal JF, Davodeau F, Cherel M, Barbet J. Different ways to improve the clinical effectiveness of radioimmunotherapy in solid tumors. J Cancer Res Ther. 2009;5:S36-S40.